26 May 2026·PIB

“CLEAR” technology can revolutionize protein imaging & facilitate detection of Cancer and Neurobiological Diseases

In this note

1. At a Glance

CLEAR (Cleavable Light-Erased Antibody Reporter) is a novel protein-imaging platform allowing visualization of an unprecedented number of proteins in a single biological sample using just one fluorescent marker [1].
Developed by Prof. Sarit S. Agasti and team at JNCASR, Bengaluru, with validation support from IISc Bengaluru scientists [2].
Enables high-resolution, multiplexed imaging of cells/tissues — direct implications for diagnosing cancer and neurobiological diseases [1].
Relevant for Prelims (S&T current affairs) and Mains GS-III (biotechnology, health/disease diagnostics).

PIB (Ministry of Science & Technology) released details of the CLEAR platform on 26 May 2026 [1].
Underlying research published in the journal Chemical Science (Royal Society of Chemistry) [1].

Proteins are the principal orchestrators of biological function and key disease-diagnosis markers; a comprehensive proteomic map of tissue (identity + spatial organisation of every protein) aids pathologists — this need motivated CLEAR [1].
Existing multiplexed-imaging techniques trade off multiplexing capacity against speed, resolution, and compatibility with delicate/live samples — CLEAR was designed to overcome this trade-off [1] [2].
CLEAR uses a "chalkboard" principle: fluorescent tags are written (labelled) and then erased to make room for new labelling, enabling repeated imaging cycles [1].

Feature	Detail
Full form	Cleavable Light-Erased Antibody Reporter (CLEAR) [1]
Nature	Novel high-plex protein-imaging platform [1]
Lead institution	JNCASR, Bengaluru [2]
Lead scientist	Prof. Sarit S. Agasti [2]
Collaborating institution	IISc Bengaluru [2]
Publishing journal	Chemical Science, Royal Society of Chemistry [1]
Ministry announcing	Ministry of Science & Technology (via PIB) [1]
Announcement date	26 May 2026 [1]
Mechanism	Light-cleavable fluorescent probes; erasure via gentle pulse of 365 nm LED light [2]
Key advantage	Combines high multiplexing, speed, high spatial resolution, and compatibility with live/delicate cells [1]

Scientific / Technological: Uses a single fluorescent marker with iterative label–image–erase cycles within the same spectral window, overcoming spectral-overlap limits of conventional multiplex imaging [1] [2].
Health / Diagnostic: Enables a comprehensive proteomic map of tissue samples in native spatial context, aiding pathologists in disease diagnosis [1].
Applications: Explicitly cited use-cases — cancer biology, immunology, and neurobiological disease research [2].
Institutional/Administrative: Indigenous development by Indian research institutions (JNCASR, IISc) under India's domestic biotech/S&T research ecosystem, publicized through Ministry of Science & Technology [1] [2].

26 May 2026: PIB release formally announcing CLEAR technology and its disease-diagnosis potential [1].

CLEAR stands for Cleavable Light-Erased Antibody Reporter [1].
CLEAR was developed at JNCASR, Bengaluru, led by Prof. Sarit S. Agasti [2].
IISc Bengaluru collaborated in validating CLEAR for complex biological systems [2].
Fluorescent signal erasure uses a 365 nm LED light pulse [2].
CLEAR research findings were published in Chemical Science journal of the Royal Society of Chemistry [1].
CLEAR uses just a single fluorescent marker to visualize an unprecedented number of proteins [1].
The announcing ministry was the Ministry of Science & Technology [1].
PIB press release date: 26 May 2026 [1].
CLEAR's working principle is compared to a "chalkboard" — write, erase, rewrite [1].
CLEAR is compatible with live cells, unlike many existing multiplex imaging techniques [1].
Target application areas: cancer, immunology, neurobiological diseases [2].

GS-III: Science & Technology — developments in biotechnology, indigenization of technology; also links to Health (disease diagnostics).
Possible question stems:
"Discuss how emerging protein-imaging technologies like CLEAR can transform disease diagnostics in India. What are the associated translational challenges?"
"Examine the significance of indigenous biotechnology innovations for India's healthcare research ecosystem, with reference to recent developments in imaging technology."
"What is multiplexed protein imaging? How does it aid in the study of cancer and neurodegenerative diseases?"

National Biotechnology Development Strategy — umbrella policy framework for biotech innovation in India.
Department of Biotechnology (DBT) schemes — funding ecosystem for such research.
Precision/Personalized Medicine — downstream application area of proteomic mapping.
Genomics vs Proteomics — conceptual distinction useful for GS-III science questions.
Cancer Genome Atlas / India's cancer research initiatives — comparative diagnostic technologies.
CRISPR and gene-editing developments in India — parallel biotech innovation theme.
Neurodegenerative disease research (Alzheimer's, Parkinson's) in India — application-linked topic.
IISc/JNCASR institutional profiles — relevant for "important research institutions" static GK.

Do not confuse CLEAR (Cleavable Light-Erased Antibody Reporter, an imaging platform) with other biology acronyms like CRISPR or CLARITY (an unrelated tissue-clearing imaging technique) — similar-sounding names are a classic MCQ trap.
Note the correct ministry is Ministry of Science & Technology, not Ministry of Health & Family Welfare, despite the disease-diagnosis angle.
The lead institution is JNCASR, not IISc — IISc's role was collaborative validation only; don't swap the two.
Remember publication venue is Chemical Science (RSC journal), not Nature or Science — a common wrong-attribution trap.
The erasing light wavelength is 365 nm (UV/LED) — don't confuse with visible-light figures.